Ascendis Pharma Reports Strong Growth Data for Achondroplasia Therapies
Event summary
- Ascendis Pharma's COACH trial shows durable growth in children with achondroplasia using TransCon CNP and hGH combination therapy, with mean AGV at or above the 97th percentile.
- TransCon CNP monotherapy demonstrated sustained improvements in height, body proportionality, and lower-limb alignment over 104 weeks in the ApproaCH trial.
- YUVIWEL® (navepegritide) achieved over 170 unique patient enrollments in the U.S., with 65% approved for reimbursement through June 30, 2026.
The big picture
Ascendis Pharma is solidifying its position in the achondroplasia treatment space with robust clinical data supporting both monotherapy and combination therapy approaches. The rapid uptake of YUVIWEL underscores the unmet need for effective therapies, while ongoing trials expand potential patient populations. Success hinges on maintaining safety profiles and securing regulatory milestones.
What we're watching
- Regulatory Progress
- Whether Ascendis can secure regulatory approval for TransCon CNP in the EU by Q4 2026 and file for infants aged 0 to <2 years.
- Commercial Uptake
- The pace at which YUVIWEL adoption accelerates beyond initial reimbursement approvals, particularly in key markets.
- Clinical Validation
- How long-term data from the AttaCH trial and combination therapy results influence market perception of TransCon CNP's efficacy.